$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000144702824000035 Filed on March 05, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.532M	$2.145M	$18.14M
YoY Change	-77.09%	-65.65%	-53.51%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.312M	$5.101M	$22.48M
YoY Change	-4.32%	20.05%	26.02%
% of Gross Profit
Research & Development	$15.40M	$17.56M	$73.70M
YoY Change	-15.72%	-23.47%	-12.69%
% of Gross Profit
Depreciation & Amortization	$355.0K	$359.0K	$1.400M
YoY Change	6.29%	16.94%	0.0%
% of Gross Profit
Operating Expenses	$20.90M	$22.89M	$96.24M
YoY Change	-13.3%	-20.53%	-7.88%
Operating Profit	-$19.36M		-$78.10M
YoY Change	11.2%		19.32%
Interest Expense	$44.00K	$1.435M	$459.0K
YoY Change	-77.78%	127.78%	-73.41%
% of Operating Profit
Other Income/Expense, Net	$1.488M		$5.254M
YoY Change	38.55%		1083.33%
Pretax Income	-$17.88M	-$19.31M	-$14.80M
YoY Change	9.4%	-11.95%	-48.43%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$17.88M	-$19.31M	-$72.85M
YoY Change	9.4%	-11.95%	4.89%
Net Earnings / Revenue	-1166.78%	-900.33%	-401.57%
Basic Earnings Per Share	-$0.10		-$0.44
Diluted Earnings Per Share	-$0.10	-$0.11	-$0.44
COMMON SHARES
Basic Shares Outstanding	179.5M shares	167.7M shares	166.0M shares
Diluted Shares Outstanding	175.6M shares		166.0M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$129.2M	$126.0M	$126.0M
YoY Change	-11.92%	-14.23%	-14.23%
Cash & Equivalents	$43.10M	$26.29M	$26.29M
Short-Term Investments	$86.14M	$99.72M	$99.72M
Other Short-Term Assets	$4.493M	$4.248M	$4.248M
YoY Change	29.78%	47.81%	47.81%
Inventory
Prepaid Expenses
Receivables	$2.139M	$1.776M	$1.776M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$135.9M	$132.0M	$132.0M
YoY Change	-11.11%	-12.65%	-12.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.414M	$4.674M	$6.090M
YoY Change	-9.05%	-7.81%	-10.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$6.284M
YoY Change			-83.18%
Other Assets		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Assets	$14.42M	$12.37M	$12.37M
YoY Change	-62.42%	-72.06%	-72.06%
TOTAL ASSETS
Total Short-Term Assets	$135.9M	$132.0M	$132.0M
Total Long-Term Assets	$14.42M	$12.37M	$12.37M
Total Assets	$150.3M	$144.4M	$144.4M
YoY Change	-21.41%	-26.11%	-26.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.743M	$3.223M	$3.223M
YoY Change	52.46%	-8.44%	-8.44%
Accrued Expenses	$5.006M	$7.473M	$7.473M
YoY Change	-34.51%	-41.98%	-41.98%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.30M	$22.49M	$22.49M
YoY Change	-19.31%	-31.56%	-31.56%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$15.36M	$15.90M	$15.90M
YoY Change	-30.68%	-38.17%	-38.17%
Total Long-Term Liabilities	$15.36M	$15.90M	$15.90M
YoY Change	-30.68%	-38.17%	-38.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.30M	$22.49M	$22.49M
Total Long-Term Liabilities	$15.36M	$15.90M	$15.90M
Total Liabilities	$35.65M	$38.38M	$38.38M
YoY Change	-24.64%	-34.46%	-34.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.295B	-$1.277B
YoY Change	6.1%	6.05%
Common Stock	$1.377B	$1.350B
YoY Change	2.83%	2.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$114.6M	$106.0M	$106.0M
YoY Change
Total Liabilities & Shareholders Equity	$150.3M	$144.4M	$144.4M
YoY Change	-21.41%	-26.11%	-26.11%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$17.88M	-$19.31M	-$72.85M
YoY Change	9.4%	-11.95%	4.89%
Depreciation, Depletion And Amortization	$355.0K	$359.0K	$1.400M
YoY Change	6.29%	16.94%	0.0%
Cash From Operating Activities	-$19.30M	-$17.29M	-$85.94M
YoY Change	-29.32%	1.78%	143.06%
INVESTING ACTIVITIES
Capital Expenditures	$95.00K	-$2.000K	$1.008M
YoY Change	-18.8%	-101.49%	96.88%
Acquisitions
YoY Change
Other Investing Activities	$11.79M	$22.22M	$51.78M
YoY Change	-29.81%	73.42%	-169.57%
Cash From Investing Activities	$11.69M	$22.23M	$50.77M
YoY Change	-29.88%	75.25%	-167.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$24.43M	3.807M	$30.65M
YoY Change	19.66%	-65.65%	-3.67%
NET CHANGE
Cash From Operating Activities	-$19.30M	-17.29M	-$85.94M
Cash From Investing Activities	$11.69M	22.23M	$50.77M
Cash From Financing Activities	$24.43M	3.807M	$30.65M
Net Change In Cash	$16.82M	8.740M	-$4.491M
YoY Change	71.63%	28.98%	-94.28%
FREE CASH FLOW
Cash From Operating Activities	-$19.30M	-$17.29M	-$85.94M
Capital Expenditures	$95.00K	-$2.000K	$1.008M
Free Cash Flow	-$19.39M	-$17.29M	-$86.94M
YoY Change	-29.28%	0.97%	142.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Revenues Revenues	18141000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	73700000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	84408000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17834000	usd
CY2022Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	10365000	usd
CY2021Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	16296000	usd
CY2023	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	3867000	usd
CY2022	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	7653000	usd
CY2023Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	6953000	usd
CY2022Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	10365000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7182000	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-34949
CY2023	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0597776
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	701 Veterans Circle
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Warminster
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	18974
CY2023	dei	City Area Code CityAreaCode	267
CY2023	dei	Local Phone Number LocalPhoneNumber	469-0914
CY2023	dei	Security12b Title Security12bTitle	Common shares, without par value
CY2023	dei	Trading Symbol TradingSymbol	ABUS
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	288128811	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	179492199	shares
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	132300000	usd
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26285000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30776000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	99718000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	116137000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1776000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1352000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4248000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2874000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	132027000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	151139000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4674000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5070000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	6284000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	37363000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1416000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1744000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	103000	usd
CY2023Q4	us-gaap	Assets Assets	144401000	usd
CY2022Q4	us-gaap	Assets Assets	195419000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10271000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16029000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	11791000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16456000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	425000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	372000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22487000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32857000	usd
CY2023Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	6953000	usd
CY2022Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	10365000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5999000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7600000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7531000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1343000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1815000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	38383000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	58567000	usd
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	169867414	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	169867414	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	157455363	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	157455363	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1349821000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1318737000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	81270000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	72406000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1276652000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1203803000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48421000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50488000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	106018000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	136852000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	144401000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	195419000	usd
CY2022	us-gaap	Revenues Revenues	39019000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	69000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2233000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	96244000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-78103000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-65456000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	5688000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	2192000	usd
CY2023	us-gaap	Interest Expense InterestExpense	459000	usd
CY2022	us-gaap	Interest Expense InterestExpense	1726000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	25000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-22000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5254000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	444000	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-72849000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-65012000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4444000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-72849000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-69456000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	165960379	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	165960379	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	150939337	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	150939337	shares
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2067000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2153000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-70782000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-71609000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	169439000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7182000	usd
CY2022	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	26000	usd
CY2022	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	20324000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	395000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	122000	usd
CY2022	abus	Stock Issued During Period Value New Issues Share Purchase Agreement StockIssuedDuringPeriodValueNewIssuesSharePurchaseAgreement	10973000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2153000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-69456000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	136852000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9301000	usd
CY2023	abus	Stock Issued During Period Value New Issues Open Market Sale Agreement StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement	29852000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	535000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	260000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2067000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-72849000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	106018000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-72849000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-69456000	usd
CY2023	us-gaap	Depreciation Depreciation	1404000	usd
CY2022	us-gaap	Depreciation Depreciation	1427000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	20000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	9301000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7182000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	69000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2233000	usd
CY2023	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	3867000	usd
CY2022	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	7653000	usd
CY2023	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	455000	usd
CY2022	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	1722000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2196000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	54000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	424000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	453000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	943000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2430000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5758000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5216000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-10664000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	22455000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-444000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-405000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-85936000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35356000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	80509000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	130430000	usd
CY2023	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	132270000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	56000000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	20000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1008000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	512000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	50773000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-74942000	usd
CY2023	abus	Proceeds From Issuance Of Common Stock Share Purchase Agreement ProceedsFromIssuanceOfCommonStockSharePurchaseAgreement	0	usd
CY2022	abus	Proceeds From Issuance Of Common Stock Share Purchase Agreement ProceedsFromIssuanceOfCommonStockSharePurchaseAgreement	10973000	usd
CY2023	abus	Proceeds From Issuance Of Common Stock Open Market Sale Agreement ProceedsFromIssuanceOfCommonStockOpenMarketSaleAgreement	29852000	usd
CY2022	abus	Proceeds From Issuance Of Common Stock Open Market Sale Agreement ProceedsFromIssuanceOfCommonStockOpenMarketSaleAgreement	20324000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	260000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	122000	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	535000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	395000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30647000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31814000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-22000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4491000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-78506000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30776000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109282000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26285000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30776000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	Organization<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of the Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arbutus Biopharma Corporation (“Arbutus” or the “Company”) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. The Company believes the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen and boosting HBV-specific immune responses. The Company’s pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, the Company had an aggregate of $132.3 million in cash, cash equivalents and investments in marketable securities. The Company had no outstanding debt as of December 31, 2023. The Company believes it has sufficient cash, cash equivalents and investments in marketable securities to fund its operations for at least the next 12 months. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company’s research and development activities and the commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company’s existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</span></div>
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	132300000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2023Q4	abus	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses and contingent liabilities as of the end or during the reporting period. Actual results could significantly differ from those estimates. Significant estimates in the accompanying consolidated financial statements impact contingent consideration, stock-based compensation, clinical trial accruals and the sale of future royalties liability.</span></div>
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20400000	shares
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></div>
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7600000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	100000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7531000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	69000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7600000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5298000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2233000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7531000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	6273000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	38129000	usd
CY2023Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	6300000	usd
CY2022Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	37400000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	37	numberofsegments
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	53	numberofsegments
CY2022Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	600000	usd
CY2023Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	600000	usd
CY2023	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	100000	usd
CY2022	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
CY2023Q4	abus	Lessee Operating Lease Numberof Leases LesseeOperatingLeaseNumberofLeases	1	lease
CY2023Q4	us-gaap	Lessor Operating Lease Renewal Term LessorOperatingLeaseRenewalTerm	P5Y
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	600000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	700000	usd
CY2023	abus	Fixed Lease Cost FixedLeaseCost	500000	usd
CY2022	abus	Fixed Lease Cost FixedLeaseCost	600000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	100000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	100000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	598000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	641000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	616000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	635000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	654000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	134000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2039000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	271000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1768000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16574000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11900000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4674000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15871000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10801000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5070000	usd
CY2023	us-gaap	Depreciation Depreciation	1400000	usd
CY2022	us-gaap	Depreciation Depreciation	1400000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3223000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3520000	usd
CY2023Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	3349000	usd
CY2022Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	3730000	usd
CY2023Q4	abus	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	2884000	usd
CY2022Q4	abus	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	8261000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	815000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	512000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10271000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16029000	usd
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.24
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	5260000	usd
CY2023	us-gaap	Restructuring Charges RestructuringCharges	1100000	usd
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	200000	usd
CY2023	abus	Liability From Sale Of Future Royalties Non Cash Expense LiabilityFromSaleOfFutureRoyaltiesNonCashExpense	455000	usd
CY2022	abus	Liability From Sale Of Future Royalties Non Cash Expense LiabilityFromSaleOfFutureRoyaltiesNonCashExpense	1722000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	11791000	usd
CY2023Q4	abus	Alnylam Entitlements AlnylamEntitlements	2	product
CY2023	us-gaap	Revenues Revenues	18141000	usd
CY2022	us-gaap	Revenues Revenues	39019000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1231450	shares
CY2023Q4	us-gaap	Employee Stock Ownership Plan Esop Shares In Esop EmployeeStockOwnershipPlanESOPSharesInESOP	1500000	shares
CY2023Q4	abus	Common Stock Discount On Shares Percentage CommonStockDiscountOnSharesPercentage	0.15
CY2023	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	290438	shares
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	171224	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	842001	shares
CY2023	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	200000	usd
CY2022	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	200000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9301000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-19668000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-17554000	usd
CY2023	abus	Effective Income Tax Rate Reconciliation Tax Withholding EffectiveIncomeTaxRateReconciliationTaxWithholding	0	usd
CY2022	abus	Effective Income Tax Rate Reconciliation Tax Withholding EffectiveIncomeTaxRateReconciliationTaxWithholding	4444000	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-2108000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	761000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	198000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	869000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1741000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	0	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign	0	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign	4444000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	179000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	324000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	18425000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14563000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	5625000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-187000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	504000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4444000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7300000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3700000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	11700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	11700000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-14800000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-87700000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-28700000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-93700000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	27300000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	16500000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	89090000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	83564000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	16726000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	16791000	usd
CY2023Q4	abus	Deferred Tax Asset Book Amortization In Excess Of Tax DeferredTaxAssetBookAmortizationInExcessOfTax	451000	usd
CY2022Q4	abus	Deferred Tax Asset Book Amortization In Excess Of Tax DeferredTaxAssetBookAmortizationInExcessOfTax	461000	usd
CY2023Q4	abus	Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes	1878000	usd
CY2022Q4	abus	Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes	2799000	usd
CY2023Q4	abus	Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements	74000	usd
CY2022Q4	abus	Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements	93000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	3375000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	3375000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	7254000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3633000	usd
CY2023Q4	abus	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Stock Options DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions	6058000	usd
CY2022Q4	abus	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Stock Options DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions	3681000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	27265000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	16471000	usd
CY2023Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	1722000	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	1507000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	322000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	387000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	114000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	153000	usd
CY2023Q4	abus	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	163711000	usd
CY2022Q4	abus	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	145287000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	163711000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	145287000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001447028-24-000035-index-headers.html	Edgar Link	pending
0001447028-24-000035-index.html	Edgar Link	pending
0001447028-24-000035.txt	Edgar Link	pending
0001447028-24-000035-xbrl.zip	Edgar Link	pending
abus-20231231.htm	Edgar Link	pending
abus-20231231.xsd	Edgar Link	pending
abus-20231231_g1.jpg	Edgar Link	pending
exhibit1015estoppelcerti.htm	Edgar Link	pending
exhibit1015estoppelcerti001.jpg	Edgar Link	pending
exhibit1015estoppelcerti002.jpg	Edgar Link	pending
exhibit1015estoppelcerti003.jpg	Edgar Link	pending
exhibit1016snda_univestxno.htm	Edgar Link	pending
exhibit101arbutus-doindemn.htm	Edgar Link	pending
exhibit1023mmcelhaughexe.htm	Edgar Link	pending
exhibit1023mmcelhaughexe001.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe002.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe003.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe004.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe005.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe006.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe007.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe008.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe009.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe010.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe011.jpg	Edgar Link	pending
abus-20231231_cal.xml	Edgar Link	unprocessable
abus-20231231_def.xml	Edgar Link	unprocessable
abus-20231231_htm.xml	Edgar Link	completed
abus-20231231_lab.xml	Edgar Link	unprocessable
exhibit1023mmcelhaughexe012.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe013.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe014.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe015.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe016.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe017.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe018.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe019.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe020.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe021.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe022.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe023.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe024.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe025.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe026.jpg	Edgar Link	pending
exhibit1023mmcelhaughexe027.jpg	Edgar Link	pending
exhibit1034separationandre.htm	Edgar Link	pending
exhibit1035finalconsulting.htm	Edgar Link	pending
exhibit211listingofsubsidi.htm	Edgar Link	pending
exhibit231eyconsent2023.htm	Edgar Link	pending
exhibit31110-kcertceo2023.htm	Edgar Link	pending
exhibit31210-kcertcfo2023.htm	Edgar Link	pending
exhibit321soxcertceo2023.htm	Edgar Link	pending
exhibit322soxcertcfo2023.htm	Edgar Link	pending
exhibit41descriptionofsecu.htm	Edgar Link	pending
exhibit97abus-incentivecom.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
abus-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2024 Q1 Form 10-K Financial Statement

#000144702824000035 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2024 Q1 Form 10-K Financial Statement

#000144702824000035 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus